Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. develops clinical-stage protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Company news centers on the rinvatercept (KER-065) program for neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, as well as elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Recurring updates include clinical data presentations, research collaborations, business highlights, financial results, and licensing economics tied to Takeda. Keros also reports governance changes, corporate presentations, portfolio prioritization, and capital actions such as its completed common-stock tender offer and capital return program.
Keros Therapeutics (KROS) reported its Q2 2020 financial results, highlighting a net loss of $10.8 million, an increase from $2.9 million in Q2 2019. The rise in losses was attributed to heightened research and development efforts, totaling $7.3 million, as well as increased general and administrative expenses amounting to $3.7 million. Keros closed its initial public offering, bringing its cash reserves to $144.7 million, projected to fund operations into 2022. The company plans to initiate multiple Phase 2 trials for its lead programs in 2021.
Keros Therapeutics announced the completion of cohorts in a Phase 1 clinical trial for its lead compound, KER-047, targeting anemias and fibrodysplasia ossificans progressiva. The trial showed target engagement and a reduction in hepcidin, indicating potential for effective iron mobilization. No serious adverse events occurred, with common side effects including headache and nausea. Keros plans to expand the trial further and expects to commence Phase 2 trials in early 2021. The study is conducted in collaboration with Mass General Brigham and NIH’s NCATS.
Keros Therapeutics (KROS), a clinical-stage biopharmaceutical firm, will be included in the Russell 2000® Index effective June 26, 2020. This index represents small-cap U.S. stocks and is utilized widely by institutional investors for benchmarking. Approximately $9 trillion in assets track Russell indexes. Keros specializes in innovative treatments for hematological and musculoskeletal disorders, with notable product candidates including KER-050, KER-047, and KER-012, targeting conditions like anemia and bone loss.
Keros Therapeutics (KROS) presented data from its Phase 1 clinical trial of KER-050 at the 25th Annual Congress of the European Hematology Association. The trial demonstrated that KER-050 was well-tolerated and elicited significant increases in key hematological parameters, including hemoglobin and platelets, in healthy post-menopausal women. Additionally, preclinical studies showed KER-050's potential to enhance hematopoiesis and offered insights into a novel ALK2 kinase inhibitor that could mitigate anemia in iron-refractory iron deficiency anemia (IRIDA) models. Keros plans to initiate Phase 2 trials for KER-050 in patients with myelodysplastic syndromes and myelofibrosis.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced that President and CEO Jasbir S. Seehra, Ph.D., will present at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 9:00 am ET. Keros is a clinical-stage biopharmaceutical company specializing in treatments for hematological and musculoskeletal disorders with significant unmet needs. Their lead candidates include KER-050 for cytopenias, KER-047 for anemia related to hepcidin, and KER-012 for bone loss disorders.
Keros Therapeutics, Inc. (KROS) reported Q1 2020 financial results and business updates. The company experienced a net loss of $11.9 million, up from $3.2 million in Q1 2019, attributed to R&D and public company transition costs. They completed a Series C financing raising $56 million in March and an IPO generating $110.4 million in April, providing a cash balance of $54.5 million as of March 31, 2020, expected to sustain operations into H2 2022. Progress continues with KER-047 and KER-050, and a Phase 2 trial for KER-050 is set for H2 2020, pending COVID-19 impacts.
Keros Therapeutics, Inc. (Nasdaq: KROS) has announced four abstracts showcasing data from its KER-050 and ALK2 hematology programs at the virtual 25th Annual Congress of the European Hematology Association (EHA) from June 11-14, 2020. Key presentations include details on KER-050's effects on hemoglobin and platelet increases, red blood cell production in cynomolgus monkeys, and its potential for treating ineffective erythropoiesis. The company plans to commence Phase 2 trials for KER-050 in patients with myelodysplastic syndromes and myelofibrosis later this year.